Transgene is designing and developing next-generation immunotherapeutics against cancer

Innovative technologies

Push the boundaries of immunotherapy

Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.

Discover our myvac® platform
Discover our invir.IO® platform

One patient, one cancer, one vaccine

TG4050 is an individualized neoantigen cancer vaccines from Transgene’s myvac® platform, based on multiple advanced genetic engineering technologies and cutting-edge artificial intelligence capabilities.
TG4050 is being evaluated in a Phase I/II clinical trial.

  TG4050 video
 Watch Alessandro Riva presenting first clinical benefits of neoantigen cancer vaccine, TG4050, in head & neck cancer at AACR 2024

Oncolytic viruses

A new generation of products

These innovative multifunctional OVs, from Transgene’s invir.IO® platform, are able to modulate the tumor microenvironment to better attack cancer.

  Oncolytic viruses video


A therapeutic vaccine in Phase II

TG4001 targets HPV-induced anogenital cancers.

  More information

Three therapeutic approaches

Transgene’s immunotherapies harness the mechanisms of the immune response to enable the patient’s body to fight against disease. 


A pioneer in viral vectors engineering, we have one ambition: design innovative treatments in the fight against cancer.

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00


© 2023 Transgene - All rights reserved